EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database

Takashi Funatogawa, Kazuma Mii, Kazuki Kojima, Yuka Aoki, Yasuaki Matsubara, Mariko Hoshiba

Modern Rheumatology · 2025

DOI: 10.1093/mr/roaf082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Takashi Funatogawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Clinical Development Department, Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324, Japan. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Scleroderma, Systemic, Biological Products, Immunosuppressive Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The 2023 EULAR guidelines for systemic sclerosis (SSc) recommend biologics (rituximab, tocilizumab), mycophenolate mofetil (MMF), and nintedanib in addition to cyclophosphamide for interstitial lung disease (ILD). This study investigated recent actual use of these drugs in Japan.

Methods

We analysed data from a Japanese hospital claims database (2020–3), identifying patients with SSc disease codes (ICD-10 M34.x) and/or ILD codes. Patients with coexisting autoimmune disease codes were also included.

Results

Of 14,522 SSc patients, 2080 (14.3%) received small-molecule drugs and 618 (4.3%) received biologics. For SSc, common first small-molecule drugs were methotrexate (24.2%), nintedanib (19.5%), tacrolimus (17.9%), and MMF (16.8%); common first biologics were rituximab (44.2%) and tocilizumab (29.1%). Of 4890 SSc-ILD patients, 1081 (22.1%) received small-molecule drugs and 282 (5.8%) received biologics. For SSc-ILD, common first small-molecule drugs were nintedanib (30.8%), tacrolimus (20.9%), and MMF (18.3%); common first biologics were rituximab (51.8%) and tocilizumab (25.2%). Rituximab showed the greatest increase in use for both SSc and SSc-ILD between 2020 and 2023. Common subsequent treatments following rituximab or intravenous cyclophosphamide (which are typically administered for a limited duration) were nintedanib, MMF, and rituximab.

Conclusions

Recent actual drug use in Japan has been aligning increasingly closely with the EULAR recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialScleroderma, SystemicBiological ProductsImmunosuppressive AgentsHumansJapanFemaleMaleMiddle AgedAgedDatabases, FactualMycophenolic AcidAntibodies, Monoclonal, HumanizedRituximabCyclophosphamideAdultIndolesEast Asian People

Stichwörter der Autor:innen

Anti-interleukin-6Japanhospital claims databaseinterstitial lung diseasesystemic sclerosis

Substanzen

tocilizumabnintedanibMycophenolic AcidAntibodies, Monoclonal, HumanizedRituximabBiological ProductsCyclophosphamideImmunosuppressive AgentsIndoles

Autor:innen und Institutionen

  • Oncology Clinical Development Department, Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324, Japan.

Zitieren

APA

Funatogawa, T., Mii, K., Kojima, K., Aoki, Y., Matsubara, Y., & Hoshiba, M. (2025). Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database. Modern Rheumatology. https://doi.org/10.1093/mr/roaf082

Vancouver

Funatogawa T, Mii K, Kojima K, Aoki Y, Matsubara Y, Hoshiba M. Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database. Modern Rheumatology. 2025. doi:10.1093/mr/roaf082

BibTeX
@article{Funatogawa2025,
  author = {Funatogawa, Takashi and Mii, Kazuma and Kojima, Kazuki and Aoki, Yuka and Matsubara, Yasuaki and Hoshiba, Mariko},
  title = {Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database},
  journal = {Modern Rheumatology},
  year = {2025},
  doi = {10.1093/mr/roaf082}
}
Kostenlos starten →